ArticleLife science alliance2026
Peroxisomal interactome mapping enables network-based modelling of function and disease.
Article in Life science alliance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peroxisomal interactome mapping enables network-based modelling of function and disease.Life science alliance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxisomal dysfunction contributes to a broad spectrum of multisystem disorders, yet mechanistic understanding and therapeutic options remain limited, posing significant challenges for clinical management. Network-based computational strategies support hypothesis generation, biomarker discovery, and drug repurposing, but their usage is constrained by incomplete human interactome coverage-especially by scarcity of high-confidence protein-protein interaction (PPI) data for peroxisomal proteins. We present the first comprehensive map of the peroxisomal interactome, generated using an automated, informatics-guided bioluminescence resonance energy transfer strategy. We profiled PPIs for 92 peroxisomal proteins and six isoforms, validating 68% of known interactions and identifying 333 novel ones. Integration with curated PPIs yielded an expanded peroxisomal interactome, enriched for drug targets and disease-associated proteins. A disease-linked subnetwork enabled prioritization of drug repurposing candidates. Tissue-specific expanded peroxisomal interactome variants, derived from transcriptomic data, revealed distinct functional submodules across nine tissues. Gene ontology analysis of 1,272 non-peroxisomal interactors suggested pathways contributing to tissue-specific vulnerability. Our approach provides a systems-level framework for mechanistic insight in peroxisomal disease, the identification of treatment targets, and application to other organelle systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.